Advertisement

Molecular Imaging and Biology

, Volume 21, Issue 2, pp 286–296 | Cite as

Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models

  • Yan Huo
  • Lei Kang
  • Xiaoxi Pang
  • Haoyuan Shen
  • Ping Yan
  • Chunli Zhang
  • Xuhe Liao
  • Xueqi Chen
  • Rongfu WangEmail author
Research Article
  • 154 Downloads

Abstract

Purpose

Tc-99m- and I-131-labeled arginine-arginine-leucine (RRL) peptides have shown the feasibility of tumor imaging in our previous studies. However, there have been no reports using RRL peptide for positron emission tomography (PET) imaging. In this study, RRL was radiolabeled with Ga-68 under optimized reaction conditions to develop a better specific and effective tumor imaging agent.

Procedures

RRL was synthesized and conjugated to a bifunctional chelating agent (DOTA-NHS), then radiolabeled with Ga-68. Labeling yield was optimized by varying pH, temperature, and reaction time and the stability was evaluated in human fresh serum. Cellular uptakes of [68Ga]DOTA-RRL and FITC-conjugated RRL in HepG2 cells were evaluated using a gamma counter, confocal microscopy, and flow cytometry. PET images and biodistribution were performed in HepG2 tumor-bearing mice after injection of [68Ga]DOTA-RRL or [68Ga]GaCl3 at different time points. Further, blocking study was investigated using cold RRL.

Results

The labeling yield of [68Ga]DOTA-RRL was 80.6 ± 3.9 % with a pH of 3.5–4.5 at 100 °C for 15 min. The cellular uptake of [68Ga]DOTA-RRL in HepG2 cells was significantly higher than that of [68Ga]GaCl3 (P < 0.05). Moreover, the high fluorescent affinity of FITC-conjugated RRL in HepG2 cells was shown using confocal microscopy and flow cytometry. After injection of [68Ga]DOTA-RRL in HepG2 tumor-bearing mice, tumor regions exhibited high radioactive accumulation over 120 min and the highest uptake at 30 min. After blocked with cold RRL, HepG2 tumors could not be visualized. [68Ga]GaCl3 was unable to show tumor images at any time point. The biodistribution results confirmed the PET imaging and blocking results.

Conclusions

Our study successfully prepared [68Ga]DOTA-RRL with a high labeling yield under the optimized reaction conditions and demonstrated its potential role as a PET imaging agent for tumor-targeted diagnosis.

Key words

Arginine-arginine-leucine (RRL) Peptide Molecular imaging Gallium-68 (68Ga) Hepatocarcinoma 

Notes

Funding Information

This study was supported by grants from the National Special Fund for the Development of Major Research Equipment and Instruments (2011YQ03011409), Twelfth “Five-Year” Plan for Science & Technology Support (2014BAA03B03), Beijing Nova Program (Z171100001117024, Z181100006218126), Beijing Capital Special Development Application Program (Z141107002514159) and Peking University First Hospital Youth Program (2017QN13, 2017QN14).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Supplementary material

11307_2018_1234_MOESM1_ESM.pdf (648 kb)
ESM 1 (PDF 647 kb)

References

  1. 1.
    Sun X, Li Y, Liu T et al (2016) Peptide-based imaging agents for cancer detection. Adv Drug Deliv Rev 110-111:38–51CrossRefGoogle Scholar
  2. 2.
    Brown CK, Modzelewski RA, Johnson CS, Wong MK (2000) A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 7:743–749CrossRefGoogle Scholar
  3. 3.
    Lu X, Wang RF (2012) A concise review of current radiopharmaceuticals in tumor angiogenesis imaging. Curr Pharm Des 18:1032–1040CrossRefGoogle Scholar
  4. 4.
    Weller GE, Wong MK, Modzelewski RA, Lu E, Klibanov AL, Wagner WR, Villanueva FS (2005) Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 65:533–539Google Scholar
  5. 5.
    Weller GE, Villanueva FS, Klibanov AL, Wagner WR (2002) Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium. Ann Biomed Eng 30:1012–1019CrossRefGoogle Scholar
  6. 6.
    Lu X, Yan P, Wang RF, Liu M, Yu MM, Zhang CL (2012) Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. Chinese J Cancer Res 24:52–59CrossRefGoogle Scholar
  7. 7.
    Kim DW, Kim WH, Kim MH, Kim CG (2015) Synthesis and evaluation of Tc-99m-labeled RRL-containing peptide as a non-invasive tumor imaging agent in a mouse fibrosarcoma model. Ann Nucl Med 29:779–785CrossRefGoogle Scholar
  8. 8.
    Yu M, Zhou H, Liu X et al (2010) Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma. Ann Nucl Med 24:13–19CrossRefGoogle Scholar
  9. 9.
    Zhao Q, Yan P, Yin L et al (2013) Validation study of (1)(3)(1)I-RRL: assessment of biodistribution, SPECT imaging and radiation dosimetry in mice. Mol Med Rep 7:1355–1360CrossRefGoogle Scholar
  10. 10.
    Zhao Q, Yan P, Wang RF et al (2013) A novel 99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study. PLoS One 8:e61043CrossRefGoogle Scholar
  11. 11.
    Lu X, Zhao L, Xue T, Zhang H (2013) Technetium-99m-Arg-Arg-Leu(g2), a modified peptide probe targeted to neovascularization in molecular tumor imaging. J BUON 18:1074–1081Google Scholar
  12. 12.
    Yao N, Yan P, Wang RF, Zhang CL, Ma C, Chen XQ, Zhao Q, Hao P (2015) Detection of pulmonary metastases with the novel radiolabeled molecular probe, 99mTc-RRL. Int J Clin Exp Med 8:1726–1736Google Scholar
  13. 13.
    Kang L, Wang RF, Yan P, Liu M, Zhang CL, Yu MM, Cui YG, Xu XJ (2010) Noninvasive visualization of RNA delivery with 99mTc-radiolabeled small-interference RNA in tumor xenografts. J Nucl Med 51:978–986CrossRefGoogle Scholar
  14. 14.
    Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, Shen B, Niu G, Chen X (2011) Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 22:2415–2422CrossRefGoogle Scholar
  15. 15.
    Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, Myschetzky R, el-Ali HH, Madsen J, Kjaer A (2014) Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. Nucl Med Biol 41:259–267CrossRefGoogle Scholar
  16. 16.
    Notni J, Pohle K, Wester HJ (2012) Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res 2:28CrossRefGoogle Scholar
  17. 17.
    Shan L (2004) 131I-Labeled arginine-arginine-leucine (RRL)-containing cyclic peptide (YCGGRRLGGC) for imaging prostate carcinoma. In: Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD)Google Scholar
  18. 18.
    Geng H, Jiang F, Wu YD (2016) Accurate structure prediction and conformational analysis of cyclic peptides with residue-specific force fields. J Phys Chem Lett 7:1805–1810CrossRefGoogle Scholar
  19. 19.
    Price EW, Orvig C (2014) Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev 43:260–290CrossRefGoogle Scholar
  20. 20.
    Poschenrieder A, Schottelius M, Schwaiger M, Wester HJ (2016) Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo—a comparison to [68Ga]pentixafor. EJNMMI Res 6:70CrossRefGoogle Scholar
  21. 21.
    Zhao N, Qin Y, Liu H, Cheng Z (2018) Tumor-targeting peptides: ligands for molecular imaging and therapy. Anti Cancer Agents Med Chem 18:74–86CrossRefGoogle Scholar
  22. 22.
    Romero E, Martinez A, Oteo M et al (2016) Preparation of 68Ga-labelled DOTA-peptides using a manual labelling approach for small-animal PET imaging. Appl Radiat Isot 107:113–120CrossRefGoogle Scholar
  23. 23.
    Tolmachev V, Velikyan I, Sandstrom M, Orlova A (2010) A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 37:1356–1367CrossRefGoogle Scholar
  24. 24.
    Mohsin H, Fitzsimmons J, Shelton T, Hoffman TJ, Cutler CS, Lewis MR, Athey PS, Gulyas G, Kiefer GE, Frank RK, Simon J, Lever SZ, Jurisson SS (2007) Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3. Nucl Med Biol 34:493–502CrossRefGoogle Scholar
  25. 25.
    Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993CrossRefGoogle Scholar
  26. 26.
    Jackson GE, Byrne MJ (1996) Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. J Nucl Med 37:379–386Google Scholar
  27. 27.
    Fortin MA, Orlova A, Malmstrom PU, Tolmachev V (2007) Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19:285–291Google Scholar

Copyright information

© World Molecular Imaging Society 2018

Authors and Affiliations

  • Yan Huo
    • 1
  • Lei Kang
    • 1
  • Xiaoxi Pang
    • 1
  • Haoyuan Shen
    • 1
  • Ping Yan
    • 1
  • Chunli Zhang
    • 1
  • Xuhe Liao
    • 1
  • Xueqi Chen
    • 1
  • Rongfu Wang
    • 1
    Email author
  1. 1.Department of Nuclear MedicinePeking University First HospitalBeijingChina

Personalised recommendations